Mota Ventures Corp. (CSE:MOTA, OTC:PEMTF, FSE:1WZ:GR) (the “Company”) would like to thank all shareholders and investors for attending yesterday’s conference call. The main items addressed on the call were the revenue, profit margins and the short- and long-term growth plans of First Class CBD (“First Class”), a wholly owned subsidiary of the Company.

The conference call will be available for playback until February 29, 2020 by dialing 1-800-319-6413 (toll free Canada/US) or +1-604-638-9010 (international), quoting access code 4038.


To date, First Class’s revenue numbers for January 2020 up to January 27th, are US$2.1M compared to US$307,000 in January of 2019, this represents an increase of 680% over the same period last year. First Class plans to continue this significant growth in their U.S. operations over the balance of 2020 as well as enter the European market.

We have four key initiatives for the next twelve months that will yield results in the near term and also position us for long-term growth. First, we will be increasing our investment in customer acquisition through our existing marketing channels. Second, we will realize efficiencies with our supply chain to reduce product costs and increase our product development pipeline. Third, we will be working to increase customer retention in our subscription model. Last, but not least, we will initiate our strategic international expansion. Our focus to-date has been on the United States market.

Our short-term product development strategy is to offer product derivations within our existing catalog. These product derivations are based on two different factors. First, we will increase the efficacy of our products by increasing CBD levels in our oil drops, creams and other products. Second, we will add additional flavor or scent options to our entire product line.

Our long-term product development strategy is to develop new and interesting products based on market demand. New products under development or testing include the following; however, launch is still fully contingent on market demand:

  • Products containing other cannabinoids outside of CBD (CBG and CGL)
  • Expansion of our CBD gummy line
  • On-the-go CBD muscle balm
  • CBD Energy Shot
  • CBD Tea
  • Products combining CBD and melatonin

“The company is excited about the continued growth of First Class CBD. Their ability to generate sales and profits positions them to become a leader in the U.S. CBD space. The partnership with Unified provides an excellent platform for further expansion in the U.S. and future expansion into Europe,” stated Joel Shacker, CEO of the Company.

The Company cautions that figures for revenue generated from the sale of First Class CBD products have not been audited, and are based on calculations prepared by management of First Class. Actual results may differ from those reported in this release once these figures have been audited.

About Mota Ventures Corp.

Mota Ventures is seeking to become a vertically integrated global CBD brand. Its plan is to cultivate and extract CBD into high-quality value-added products from its Latin American operations and distribute it both domestically and internationally. Its existing operations in Colombia consist of a 2.5-hectare site that has optimal year-round growing conditions and access to all necessary infrastructure. Mota Ventures a seeking to become a vertically integrated, revenue-producing CBD company with operations in both Europe and North America. Mota is looking to establish sales channels and a distribution network internationally through the acquisition of the Sativida and First Class CBD brands. Low cost production, coupled with international, direct to customer sales channels will provide the foundation for the success of Mota Ventures.

ON BEHALF OF THE BOARD OF DIRECTORS
MOTA VENTURES CORP.

Joel Shacker
Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President & CEO at +604.423.4733 or by email at IR@motaventuresco.com or www.motaventuresco.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to the short- and long-term plans of First Class CBD, key initiatives in the next twelve months, its plans to become a vertically integrated global CBD brand, its plans to cultivate and extract cannabis to produce CBD and high-quality value added CBD products in Latin America for distribution domestically and internationally and its plans to acquire revenue-producing CBD brands and operations in Europe and North America. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Click here to see the educational profile for Mota Ventures (CSE:MOTA, FSE:1WZ:GR, OTC:PEMTF) and to request an investor presentation.

Source

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less